Form 4: Tyra Biosciences Director Acquires Stock Options

Tyra Biosciences Director Rehan Verjee was granted stock options for 13,160 shares of common stock under the company's Non-Employee Director Compensation Program.

Summary

• Rehan Verjee, a Director at Tyra Biosciences, Inc., was granted stock options on May 28, 2026.
• The options are for 13,160 shares of common stock with an exercise price of $32.68 per share.
• These options are part of the company's Non-Employee Director Compensation Program.
• Vesting occurs monthly, with 1/12th of the shares vesting each month following the grant date.
• Any unvested portion will vest on the date of the next annual stockholders' meeting if it occurs before the first anniversary of the grant date, provided continuous service is maintained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director compensation through stock options aligns management incentives with shareholder value.
• The grant of options indicates continued confidence in the company's future prospects by a key insider.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The exercise price of $32.68 is a significant hurdle, requiring substantial stock price appreciation for the options to become profitable.
• The grant is a non-cash compensation, which does not directly inject capital into the company.

Risks

• The value of the stock options is directly tied to the future performance and stock price of Tyra Biosciences, which carries inherent market risks.
• If the company's stock price does not exceed $32.68 per share, the options may expire worthless.
• The vesting is contingent on continuous service, meaning any departure before vesting would result in forfeiture of unvested options.

Future Outlook

The stock options granted have an expiration date of May 27, 2036, and vest over time, contingent on the director's continued service and the company's annual meeting schedule.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to attract and retain experienced leadership while aligning their interests with long-term shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Rehan Verjee is a related party transaction, as he is an insider of Tyra Biosciences, Inc.

Stakeholder Impact

• Shareholders: The grant itself does not immediately impact share price but represents future potential dilution if options are exercised. It aligns director incentives with long-term shareholder value.
• Employees: No direct impact, but reflects the company's compensation strategy for its board.
• Management: Reinforces the standard compensation structure for non-employee directors.

Next Steps

• Director Rehan Verjee will continue to vest in the stock options over the next 12 months, subject to continuous service.
• The company will continue to operate under its Non-Employee Director Compensation Program for future grants.

Key Dates

Keywords

Tyra Biosciences, Form 4, Stock Options, Director Compensation, Insider Trading, SEC Filing, Equity Award, Vesting Schedule